TP53 Gene Mutations in Prostate Cancer Progression

We assessed the predictive value of TP53 mutations and prostate-specific antigen (PSA) for tumor progression in prostate cancer (PCa) patients. Ninety tumor tissue samples of patients with PCa from radical prostatectomy were used. Tumor progression was estimated biochemically by the PSA level (>...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2010-05, Vol.30 (5), p.1579-1586
Main Authors: ECKE, Thorsten H, SCHLECHTE, Horst H, SCHIEMENZ, Katrin, SACHS, Markus D, LENK, Severin V, RUDOLPH, Birgit D, LOENING, Stefan A
Format: Article
Language:English
Subjects:
Biological and medical sciences
Disease Progression
DNA Mutational Analysis
Exons
Genes, p53
Humans
Male
Medical sciences
Middle Aged
Mutation
Neoplasm Metastasis
Nephrology. Urinary tract diseases
Prostate-Specific Antigen - chemistry
Prostatectomy - methods
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Risk Factors
Temperature
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We assessed the predictive value of TP53 mutations and prostate-specific antigen (PSA) for tumor progression in prostate cancer (PCa) patients. Ninety tumor tissue samples of patients with PCa from radical prostatectomy were used. Tumor progression was estimated biochemically by the PSA level (> 0.2 microg/l) or by detection of metastases. Screening for TP53 mutations was performed by temperature gradient gel electrophoresis (TGGE) in exon-specific manner. Follow-up data were collected from medical protocols. Statistical analysis was performed by uni- and multivariate techniques. In 32 out of 90 patients (35.6%), TP53 mutations were detected. Thirteen out of 32 patients (40.6%) with TP53 mutations and nine out of 58 patients (15.5%) with TP53 wild-type showed tumor progression after 25 and 45 months, respectively. TP53 mutations in exon 7 and exon 8 are factors of tumor progression in PCa. Their contribution to tumor recurrence is more significant than tumor stage and pretherapeutic PSA level.
ISSN:0250-7005
1791-7530